Regeneron Pharmaceuticals
Regeneron Pharmaceuticals · Biotech
01Wall Street Consensus
02Earnings Results
Key Takeaways
- Non-GAAP EPS $9.47 — beat consensus $8.68 by +9.1%
- Revenue $3.605B — beat consensus $3.483B by +3.5%, +19% YoY
- Dupixent global net sales $4.9B (+33% YoY) — Sanofi record
- Eylea HD US revenue $468M (+52% YoY) — demand rising
- Libtayo global net sales $438M (+54% YoY)
- $803M of buybacks plus a new $3.0B authorization
- Quarterly dividend of $0.94 declared
Key Checkpoints
- 01Dupixent revenue — whether Q1 growth continues from Q4 2025 $3.8B+ run rate
- 02Eylea/Eylea HD market share — biosimilar penetration pace
- 03Libtayo (immuno-oncology) revenue growth — first-line indication expansion effect
- 04R&D pipeline: linvoseltamab (bispecific), itepekimab (asthma) clinical progress
- 05Gross Margin 90%+ maintenance — biotech industry-leading level
- 06FY2026 Dupixent revenue guidance $16B+ trajectory achievement
Upside Catalysts
- Dupixent indication expansion: COPD, eosinophilic esophagitis and more expanding TAM to $30B+
- linvoseltamab (BCMAxCD3 bispecific): multiple myeloma potential blockbuster
- Eylea HD: high-dose formulation extending dosing intervals - differentiating from biosimilars
- Obesity therapeutics pipeline: GLP-1 + other mechanism combination approach
- Premier defensive positioning: zero exposure to oil prices, Iran war, TurboQuant, or trade disruptions - pure biotech with predictable revenue streams attracting institutional safe-haven flows amid global equity selloff
Risk Factors
- Eylea biosimilars: Amgen Pavblu and others launching - Eylea revenue 30-40% decline risk
- Drug pricing regulation: IRA price negotiation scope expansion - Dupixent potentially subject in future
- Dupixent competition: AbbVie dupilumab follow-on + IL-13 target competing drugs
- Iran war escalation driving broader market volatility - S&P Q1 -4.2%, though healthcare relatively insulated
- R&D failure risk: late-stage pipeline failures would damage growth narrative
EEPS History (Last 12 Quarters)
Actual EPS vs Consensus — Green Beat · Red Miss
1Final Assessment
Regeneron is a franchise biotech centered on Dupixent ($16B+ annual revenue trajectory). Consensus EPS $8.25, Revenue $4.35B. Dupixent's indication expansion (COPD, eosinophilic esophagitis) is expanding TAM to $30B+.
The key risk is Eylea biosimilar penetration. Amgen Pavblu and others launched in 2025 could drive Eylea revenue down 30-40% annually, though Eylea HD (high-dose) is attempting differentiation.
In the current environment of extreme market stress - Iran war escalation (Trump's 4/2 speech: 2-3 more weeks of energy facility strikes, Brent $107+, Hormuz Strait summit with 35-40 nations yielding no resolution), S&P Q1 -4.2%, Nasdaq Q1 -7.8%, KOSPI -4.37% crash - REGN is one of the purest defensive plays available. Zero correlation to energy prices, no semiconductor exposure, no TurboQuant risk. Institutional fund rotation into quality healthcare is accelerating.
2Dupixent Franchise
Dupixent (dupilumab):
- 2025 global revenue: $14B+ (Sanofi partnership)
- FY2026 target: $16B+
- Indications: Atopic dermatitis, asthma, nasal polyps, eosinophilic esophagitis, COPD, prurigo nodularis
- COPD indication approval (2024) significantly expanding TAM
- Pediatric indication expansion continuing patient pool growth
Competitive Landscape:
- AbbVie: Developing next-gen IL-13 antibody
- Sanofi: Dupixent marketing partner (revenue sharing)
- Biosimilar risk: Dupixent patent-protected until 2031
3Eylea & Pipeline
Eylea/Eylea HD:
- Eylea original formulation: Revenue pressure from biosimilars (Amgen Pavblu, etc.)
- Eylea HD: 8mg high-dose extending dosing intervals to 12-16 weeks
- HD conversion rate is key to biosimilar defense
- Ophthalmology market: $15B+ TAM
Key Pipeline:
- linvoseltamab (BCMAxCD3 bispecific): Multiple myeloma — blockbuster potential
- itepekimab: Moderate-to-severe asthma (IL-33 target)
- fianlimab (anti-LAG-3): Immuno-oncology combination therapy
- odronextamab: Non-Hodgkin lymphoma
- Obesity therapeutics: Early-stage research
R&D Investment:
- $5B+ annual R&D spending — industry-leading R&D efficiency
SEPS 서프라이즈 히스토리
분기별 EPS 컨센서스 대비 서프라이즈(%) — 막대: EPS, 점선: 매출
컨센서스 대비 실제 EPS/매출 서프라이즈 (%)